Close this search box.

Access Issues Loom Large at Munich Workshop on Biologics and Biosimilars

When should patients switch from one medicine to another for non-medical reasons?  How can pharmacovigilance processes successfully monitor patients’ reactions to a medicine? And, perhaps most importantly, how do we ensure that patients are informed participants in decisions about their medication?